Taysha Gene Therapies, Inc. Stock Price, News & Analysis

Taysha Gene Therapies (Nasdaq: TSHA) announced new preclinical data showcasing advancements in its gene therapy pipeline, emphasizing TSHA-113, which reduced tau expression in mouse models for tauopathies. Taysha plans to advance five programs into IND/CTA-enabling studies and file an IND for one candidate by year-end 2021. The company reported a significant commercial opportunity for therapies targeting various CNS diseases affecting large patient populations, including Alzheimer's, with a combined estimate of over 6 million Americans affected.

Taysha Gene Therapies (Nasdaq: TSHA) has acquired exclusive global rights to TSHA-120, a clinical-stage AAV9 gene therapy for giant axonal neuropathy (GAN). This therapy is currently in an NIH-led clinical trial, having received FDA designations as a rare pediatric disease and orphan drug. TSHA-120 shows promise in halting disease progression, with significant improvements in motor function observed in treated patients. The potential market opportunity is over $2 billion for approximately 2,400 patients in the U.S. and Europe. Taysha plans to engage with regulatory agencies to expedite the approval process.

Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in two upcoming virtual conferences: the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 10:15 am ET and the Chardan 5th Annual Manufacturing Summit on April 26, 2021, at 1:00 pm ET. Both events will feature fireside chats led by key executives, including the President and CEO, RA Session II, along with others from the company.

Webcasts of these events can be accessed on the Taysha corporate website, with archived versions available for 60 days.

Taysha Gene Therapies (Nasdaq: TSHA) announced its upcoming participation in virtual fireside chats at the Oppenheimer 31^st Annual Healthcare Conference on March 16, 2021, at 1:50 pm ET, and at Stifel’s 3^rd Annual CNS Day on March 31, 2021, at 10:30 am ET. Both events will feature RA Session II, President, Founder and CEO. Audio webcasts will be available in the “Events & Media” section of Taysha's corporate website for 60 days after the events.

Taysha Gene Therapies (Nasdaq: TSHA) announced a multi-year collaboration with Yale University to develop next-generation mini-gene payloads for AAV gene therapies targeting neurodevelopmental disorders. This partnership follows previous collaborations with Cleveland Clinic and UT Southwestern, focusing on overcoming challenges in gene therapy. Yale's researchers will create payloads aimed at treating disorders like intellectual disability, while UTSW will produce and evaluate the viral vector constructs. This initiative aims to expand the range of genetic diseases treatable by AAV-based therapies.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) reported its financial results for 2020, highlighting a net loss of $60 million or $3.40 per share, with R&D expenses at $31.9 million. The company successfully expanded its pipeline from 18 to 25 gene therapy candidates and anticipates significant clinical milestones in 2021, including initiating trials for TSHA-101, TSHA-102, and TSHA-104. Taysha raised approximately $307 million since inception, with $165.9 million net from its IPO, and aims to enhance its technologies and workforce throughout the year.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced it will report its financial results for the full year ended December 31, 2020, during a corporate update conference call on March 3, 2021, at 8:00 AM ET. The company focuses on developing AAV-based gene therapies for monogenic diseases of the central nervous system (CNS) and aims to translate treatments quickly from research to clinical applications. Taysha's collaboration with the UT Southwestern Gene Therapy Program enhances its pipeline targeting both rare and large patient populations.

Taysha Gene Therapies (Nasdaq: TSHA) announces its support for Rare Disease Day by launching the #RareAlly initiative, aimed at recognizing those in the rare disease community who provide inspiration and motivation. The initiative includes a photo submission campaign to raise funds for the rare disease community and an employee event with a guest speaker from the UT Southwestern Gene Therapy Program. Taysha emphasizes the collective efforts needed to advance treatment options for rare diseases, affecting approximately 300 million people globally.

Taysha Gene Therapies (Nasdaq: TSHA) has established an independent Scientific Advisory Board (SAB) to enhance its clinical development and commercialization efforts. This board comprises renowned experts in gene therapy and CNS diseases. CMO Suyash Prasad emphasized the board's potential to contribute significantly to the company’s AAV-based gene therapy pipeline. The SAB includes distinguished professionals like Deborah Bilder, Alan Boyd, Wendy K. Chung, David P. Dimmock, Michael W. Lawlor, and Gerald S. Lipshutz, each bringing extensive experience to the table.